The biopharmaceutical company Curevac stops development of a corona vaccine.
(Photo: imago images / ULMER press picture agency)
Dusseldorf The realignment of the Tübingen company Curevac is not well received on the stock market. After this news, the shares initially slipped by more than 15 percent and were quoted at around 32 euros on Tuesday noon. At the end of trading, the minus was just under eight percent.
The biotech company is giving up its Covid vaccine and instead wants to focus more on the successor product and the alliance with Glaxo-Smithkline. De facto, this makes Curevac a biotech company that is still in the early stages of its development. The news had no impact on the share price of the former cooperation partner Bayer, which was supposed to produce the vaccine in large numbers. The Bayer paper remained 1.8 percent in the red.
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further